ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AKER Akers Biosciences Inc

2.47
0.00 (0.00%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Akers Biosciences Inc NASDAQ:AKER NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.47 2.41 2.50 0 01:00:00

Small Company Offering and Sale of Securities Without Registration (d)

07/04/2020 10:11pm

Edgar (US Regulatory)


o NoneEntity Type
0001321834
Akers Biosciences Inc
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 Akers Biosciences, Inc.
Jurisdiction of Incorporation/OrganizationNEW JERSEY 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 Akers Biosciences, Inc. 
Street Address 1Street Address 2
 201 GROVE ROAD 
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 THOROFARE NEW JERSEY 08086 (856) 848-8698 



3. Related Persons
Last NameFirst NameMiddle Name
YeatonHoward
Street Address 1Street Address 2
201 Grove Road
CityState/Province/CountryZIP/Postal Code
ThorofareNEW JERSEY08086
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 Interim Chief Financial Officer

Last NameFirst NameMiddle Name
SchreiberChristopherC.
Street Address 1Street Address 2
201 Grove Road
CityState/Province/CountryZIP/Postal Code
ThorofareNEW JERSEY08086
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 Executive Chairman of the Board of Directors; Principal Executive Officer

Last NameFirst NameMiddle Name
SilvermanJoshua
Street Address 1Street Address 2
201 Grove Road
CityState/Province/CountryZIP/Postal Code
ThorofareNEW JERSEY08086
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
WhiteBillJ.
Street Address 1Street Address 2
201 Grove Road
CityState/Province/CountryZIP/Postal Code
ThorofareNEW JERSEY08086
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

 
Last NameFirst NameMiddle Name
SchroederRobertC.
Street Address 1Street Address 2
201 Grove Road
CityState/Province/CountryZIP/Postal Code
ThorofareNEW JERSEY08086
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  o Pharmaceuticals  o Telecommunications
  o Investment Banking  x Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2020-03-23 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests x Equity
o Tenant-in-Common Securities o Debt
o Mineral Property Securities o Option, Warrant or Other Right to Acquire Another Security
x Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
  
(Associated) Broker or Dealer o None(Associated) Broker or Dealer CRD Number o None
  
Street Address 1Street Address 2
  
City State/Province/CountryZIP/Postal Code
   
State(s) of Solicitation o All States
 
 



13. Offering and Sales Amounts
Total Offering Amount $ 2718057 USD o Indefinite
Total Amount Sold $ 1233057 USD 
Total Remaining to be Sold $ 1485000 USD o Indefinite
 
Clarification of Response (if Necessary)
 Upon the achievement of certain milestones, the Company shall issue an additional 750,000 shares of its common stock, equal to $1,485,000 of the above listed total offering amount.


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 4


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 0 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
  


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o

1 Year Akers Biosciences Chart

1 Year Akers Biosciences Chart

1 Month Akers Biosciences Chart

1 Month Akers Biosciences Chart

Your Recent History

Delayed Upgrade Clock